Advances in Single-Cell Sequencing Technology and its Applications in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and is mainly treated with chemotherapy-based combination therapy. In recent years, the increasing development of single-cell sequencing (SCS) has become one of the most promising technologies in the field of biotechnology. The study of the heterogeneity of TNBC tumor cells using SCS will expand our current knowledge of metastasis, drug resistance mechanisms, mutations, and cloning in these cells; this will further guide clinical chemotherapy, targeted therapy, and immunotherapy. Relevant studies shown that SCS exactly plays an important role in clinical diagnosis and treatment. To highlight the role of SCS in the study of TNBC, we elaborate on the progress of research and the applications of SCS in TNBC.